You are here: Industry Insights > NASH drug

News List

Ascletis receives IND approval for its NASH drug biospectrumasia
August 28, 2019
ASC40 is an orally bioavailable, first-in-class inhibitor of fatty acid synthase (FASN)
Gilead NASH drug fails late stage trial pharmaphorum
February 13, 2019
Gilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial.
With Gilead and rivals deep in phase 3, FDA unveils draft guidance on NASH drug development fiercebiotech
January 02, 2019
The FDA has published draft guidance on developing NASH drugs that has implications for Gilead and the host of other companies targeting the indication.....
Midphase failure of Novartis’ NASH drug crushes Conatus fiercebiotech
December 29, 2018
A phase 2b trial of Conatus Pharmaceuticals’ emricasan has missed its primary endpoint. The setback wiped 55% off Conatus’ stock in premarket trading as investors digested the implications of a second midphase failure in eight months.....
Gilead pushes on with NASH drug after phase 2 success pharmaphorum
December 06, 2018
Gilead Sciences presented promising data on its research into advanced fibrosis caused by non-alcoholic steatohepatitis (NASH), one of several big pharma companies developing drugs for the currently untreatable disease.
Shire’s fast-track NASH drug abruptly stopped in phase 2 fiercebiotech
August 01, 2018
Shire has quietly cut the trial of an FDA fast-tracked fatty liver disease drug, although it’s not giving much away about what happened.